VANCOUVER, BC / March 6, 2015 / Vodis Pharmaceuticals Inc. (the “Company” or “Vodis”) (VP:CNX) (1JV.F) announces a non-brokered private placement offering 5,000,000 common shares (“Common Shares”) of the Company at a subscription price of $0.10 per share.
In connection with the financing, finders’ fee will comprise 7% cash commission and a 7% finders’ Warrants commission. The proceeds of the private placement will be used for expansion into Washington State, USA and general working capital purposes.
About Vodis Pharmaceuticals
Vodis is one of Canada’s foremost brand names in the medical marijuana business. While awaiting for the inspection date from Health Canada to become a Licensed Producer at its state-of-the-art 12,000 square foot facility in British Columbia, the Vodis management team reinforces its commitment to the Continues Improvement Process (CIP) by continuously reviewing its internal Standard Operating procedures and external training of its staff.
For further information please contact:
CEO & Director
104-1037 West Broadway
Vancouver, BC V6H 1E3
direct: 1-866-210-1420 ext. 102
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. All of the forward-looking statements made in this news release and any accompanying graphic links are qualified by these cautionary statements and those in our continuous disclosure filings available on SEDAR at www.sedar.com. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
This news release, required by applicable Canadian laws, is not for distribution to U.S. news services or for dissemination in the United States and does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer